Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Steven W Pipe, Midori Shima, Michaela Lehle, Amy Shapiro, Sammy Chebon, Katsuyuki Fukutake, Nigel S Key, Agnès Portron, Christophe Schmitt, Maria Podolak-Dawidziak, Nives Selak Bienz, Cedric Hermans, Avrita Campinha-Bacote, Anna Kiialainen, Kathelijne Peerlinck, Gallia G Levy, Victor Jiménez-Yuste

Open source

DOI: 10.1016/s2352-3026(19)30054-7
Published: 2019-06
Container: The Lancet Haematology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-19-30054-7,
  title = {Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study},
  author = {Steven W Pipe and Midori Shima and Michaela Lehle and Amy Shapiro and Sammy Chebon and Katsuyuki Fukutake and Nigel S Key and Agnès Portron and Christophe Schmitt and Maria Podolak-Dawidziak and Nives Selak Bienz and Cedric Hermans and Avrita Campinha-Bacote and Anna Kiialainen and Kathelijne Peerlinck and Gallia G Levy and Victor Jiménez-Yuste},
  year = {2019},
  journal = {The Lancet Haematology},
  doi = {10.1016/s2352-3026(19)30054-7},
  url = {https://doi.org/10.1016/s2352-3026(19)30054-7}
}

RIS

TY  - JOUR
TI  - Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
AU  - Steven W Pipe
AU  - Midori Shima
AU  - Michaela Lehle
AU  - Amy Shapiro
AU  - Sammy Chebon
AU  - Katsuyuki Fukutake
AU  - Nigel S Key
AU  - Agnès Portron
AU  - Christophe Schmitt
AU  - Maria Podolak-Dawidziak
AU  - Nives Selak Bienz
AU  - Cedric Hermans
AU  - Avrita Campinha-Bacote
AU  - Anna Kiialainen
AU  - Kathelijne Peerlinck
AU  - Gallia G Levy
AU  - Victor Jiménez-Yuste
PY  - 2019
JO  - The Lancet Haematology
DO  - 10.1016/s2352-3026(19)30054-7
UR  - https://doi.org/10.1016/s2352-3026(19)30054-7
ER  -

APA

Pipe, S. W., Shima, M., Lehle, M., Shapiro, A., Chebon, S., Fukutake, K., Key, N. S., Portron, A., Schmitt, C., Podolak-Dawidziak, M., Bienz, N. S., Hermans, C., Campinha-Bacote, A., Kiialainen, A., Peerlinck, K., Levy, G. G., & Jiménez-Yuste, V. (2019). Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(19)30054-7

Source records

crossref · retrieved 2026-09-27T14:05:29.701Z